# A Trial for Relapsed Multiple Myeloma Patients (Isatuximab-dexamethasone)

> **NCT04965155** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **EMN Trial Office S.r.l. Impresa Sociale** · enrollment: 50 (estimated)

## Conditions studied

- Relapsed Multiple Myeloma

## Interventions

- **DRUG:** Isatuximab-dexamethasone

## Key facts

- **NCT ID:** NCT04965155
- **Lead sponsor:** EMN Trial Office S.r.l. Impresa Sociale
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-03-21
- **Primary completion:** 2023-11-28
- **Final completion:** 2027-03-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04965155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04965155, "A Trial for Relapsed Multiple Myeloma Patients (Isatuximab-dexamethasone)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04965155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*